Journey Medical to Participate in Two Investor Conferences in October 2025.
PorAinvest
miércoles, 8 de octubre de 2025, 8:33 am ET1 min de lectura
DERM--
The 4th Annual ROTH Healthcare Opportunities Conference, set for Thursday, October 9, will feature one-on-one meetings with members of Journey Medical's management team. This event offers investors a direct opportunity to discuss the company's strategies and performance with key executives.
The ThinkEquity Conference, taking place on Thursday, October 30, will include a presentation by the management team followed by one-on-one meetings. This format allows investors to gain a broader understanding of the company's initiatives and ask questions in a more structured setting.
Journey Medical Corporation is focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded FDA-approved prescription drugs that help treat and heal common skin conditions.
The company's management team comprises industry experts with extensive experience in developing and commercializing successful dermatology prescription brands. Journey Medical is located in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). The company's common stock is registered with the U.S. Securities and Exchange Commission (SEC) and files periodic reports with the SEC.
For additional information about Journey Medical, investors can visit the company's website at [www.journeymedicalcorp.com](http://www.journeymedicalcorp.com).
Journey Medical Corporation, a commercial-stage pharmaceutical company, announced that its management team will participate in two investor conferences in October 2025. The 4th Annual ROTH Healthcare Opportunities Conference will take place in New York City on October 9, featuring 1x1 meetings. The ThinkEquity Conference will occur in New York City on October 30, with a presentation and 1x1 meetings. Journey Medical primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions.
Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in dermatology treatments, has announced that its management team will participate in two investor conferences in October 2025. The events, both scheduled in New York City, aim to provide investors with insights into the company's ongoing efforts and future prospects.The 4th Annual ROTH Healthcare Opportunities Conference, set for Thursday, October 9, will feature one-on-one meetings with members of Journey Medical's management team. This event offers investors a direct opportunity to discuss the company's strategies and performance with key executives.
The ThinkEquity Conference, taking place on Thursday, October 30, will include a presentation by the management team followed by one-on-one meetings. This format allows investors to gain a broader understanding of the company's initiatives and ask questions in a more structured setting.
Journey Medical Corporation is focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded FDA-approved prescription drugs that help treat and heal common skin conditions.
The company's management team comprises industry experts with extensive experience in developing and commercializing successful dermatology prescription brands. Journey Medical is located in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). The company's common stock is registered with the U.S. Securities and Exchange Commission (SEC) and files periodic reports with the SEC.
For additional information about Journey Medical, investors can visit the company's website at [www.journeymedicalcorp.com](http://www.journeymedicalcorp.com).
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios